| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
T0070907 (T-0070907; T 0070907) is a potent and selective PPARγ (Peroxisome proliferator-activated receptor γ) inhibitor with potential anti-inflammatory activity. It inhibits PPARγ with an IC50 of 1 nM in a cell-free assay.
| ln Vitro |
ME-180 and SiHa cells exposed with 4 Gy of radiation exhibit impaired IR-induced DNA DSB repair following pretreatment with T0070907 (50 μM). In ME-180 and SiHa cells, T0070907 (0-50 μM) dramatically lowers DNA-PKcs and RAD51 protein levels [1]. In ME180 and SiHa cells, T0070907 (50 μM) treatment inhibits DNA synthesis, suppresses radiation-induced alterations in cell cycle regulatory proteins, and decreases α- and β-tubulin levels in a time-dependent way [2]. T0070907 (10 μM) exhibits cytotoxicity that is unique to adipocytes and not dependent on PPARγ. Oxidative stress in immature adipocytes is elevated by T0070907 [3]. T0070907 (1 μM) prevents the adipogenic cell line 3T3-L1 from being treated in a way that induces adipogenesis. T0070907 covalently alters human PPAR 2 helix 3's cysteine 313 [4].
|
||
|---|---|---|---|
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
|
||
| Additional Infomation |
2-chloro-5-nitro-N-pyridin-4-ylbenzamide is a carbonyl compound and an organohalogen compound.
|
| Molecular Formula |
C12H8CLN3O3
|
|
|---|---|---|
| Molecular Weight |
277.66
|
|
| Exact Mass |
277.025
|
|
| CAS # |
313516-66-4
|
|
| Related CAS # |
|
|
| PubChem CID |
2777391
|
|
| Appearance |
White to light yellow solid powder
|
|
| Density |
1.5±0.1 g/cm3
|
|
| Boiling Point |
381.7±37.0 °C at 760 mmHg
|
|
| Flash Point |
184.6±26.5 °C
|
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
|
| Index of Refraction |
1.684
|
|
| LogP |
2.25
|
|
| Hydrogen Bond Donor Count |
1
|
|
| Hydrogen Bond Acceptor Count |
4
|
|
| Rotatable Bond Count |
2
|
|
| Heavy Atom Count |
19
|
|
| Complexity |
342
|
|
| Defined Atom Stereocenter Count |
0
|
|
| InChi Key |
FRPJSHKMZHWJBE-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C12H8ClN3O3/c13-11-2-1-9(16(18)19)7-10(11)12(17)15-8-3-5-14-6-4-8/h1-7H,(H,14,15,17)
|
|
| Chemical Name |
2-chloro-5-nitro-N-(pyridin-4-yl)benzamide
|
|
| Synonyms |
T-0070907; T 0070907; T0070907;
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (3.60 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1 mg/mL (3.60 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1 mg/mL (3.60 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 1% DMSO+30% polyethylene glycol+1% Tween 80: 30mg/mL |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6015 mL | 18.0076 mL | 36.0153 mL | |
| 5 mM | 0.7203 mL | 3.6015 mL | 7.2031 mL | |
| 10 mM | 0.3602 mL | 1.8008 mL | 3.6015 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|---|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
